Upper Airways Research Laboratory Department of Otorhinolaryngology Advanced treatments of nasal polyposis: Anti-IL-5 and Anti-IgE Which for whom? Prof.

Slides:

Advertisements

Similar presentations

Advertisements

Severe Chronic Upper Respiratory Disease: Phenotyping Inflammation

Chronic RhinoSinusitis- State of the Art

Management of Rhinitis in Patients with Asthma Michael Schatz, MD, MS Chief, Department of Allergy Kaiser Permanente, San Diego, CA.

Sniffing out the problem Jonathan Hern. Commissioning Guide for Chronic Rhinosinusitis ENTUK and RCS Based on European position paper on sinusitis Guidance.

Pathogenesis AND treatment of Chronic Rhinosinusitis 1.

NDAC December 14, Clinical Endpoints for Nasal Decongestants Xu Wang, M.D., Ph.D. Medical Officer Division of Pulmonary and Allergy Products Nonprescription.

Immunology of Asthma through Biologics Private Practice & St Michael’s Hospital Lecturer, Division of Clinical Immunology & Allergy Department of Medicine,

Smoking Cessation in Smokers Motivated to Quit Presented at American College of Cardiology Scientific Sessions 2004 Presented by Dr. Robert Anthenelli.

HIGH DOSES OF VITAMIN D TO REDUCE EXACERBATION IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE: A RANDOMIZED TRIAL An Lehouck, PhD; Chantal Mathieu, MD, PhD;

Nasal Polyps - Pathogenesis and Treatment Implications

BEAUTI f UL: morBidity-mortality EvAlUaTion of the I f inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction Purpose.

Our Experiences With Natural Natural Products As Potential Therapeutic Agents : Towards Safer & Cost Effective Therapy Dr. Mrs.Chanda Kulkarni. MBBS; MD;

The Medical Management of Infective & Allergic Rhinitis Joe Marais FRCS(ORL) Hillingdon Hospital, Northwick Park Hospital, Bishops Wood.

Sarah Struthers, MD March 19, 2015

Diagnostic approach to the allergic patient. Allergic conditions in Israel.

1 Environmental Exposure Units for Phase 3 Studies Ronald L. Rabin, MD Chief, Laboratory of Immunobiochemistry Center for Biologics Evaluation and Research.

ENT Department Upper Airways Research Laboratory New insights in the pathophysiology of chronic rhinosinusitis Upper Airways Research Laboratory Department.

Interaction between acetaminophen and warfarin in adults receiving long-term oral anticoagulants: a randomized controlled trial นศภ. ณัฐวุฒิ ดวงแดง มหาวิทยาลัยเชียงใหม่

Corticosteroids in adults with bacterial meningitis

FDA Advisory Committee May 15, 2003 Genentech Marketing Application STN / 0 Omalizumab Recombinant human anti-IgE for treatment of asthma Efficacy.

Downloaded from – Use of Montelukast for the Treatment of Seasonal (Spring) Allergic Rhinitis.

BEST: Beta-blocker Evaluation Survival Trial Purpose To determine whether the β-blocker bucindolol reduces morbidity and mortality in patients with advanced.

ISIS-4: Fourth International Study of Infarct Survival Purpose To assess the separate and combined effects on all-cause mortality of adding early captopril,

CHRONIC SINUSITIS IN MALAYSIA NAQIBAH AFIQAH BINTI NADZRI NURLINA BINTI WANSHAH.

Thrice-Weekly Glatiramer Acetate for Relapsing Forms of Multiple Sclerosis: Findings from the GALA Study Fred D. Lublin, MD Saunders Family Professor of.

A Pharmacokinetic Drug Interaction Study of Drug-72 and Drug-12 Department of Mathematic & Statistics York University Yufeng Lin Xiaofeng Zhou.

Pharmacologic Treatment Of Asthma 1 د. ميريانا البيضة.

내과 R2 이지훈 N Engl J Med Sep 8.

Effect of Spironolactone on Diastolic Function and Exercise Capacity in Patients with Heart Failure with preserved Ejection Fraction Effect of Spironolactone.

Joint Non-Prescription Drugs and Pediatric Advisory Committee Meeting October 18-19, 2007 Considerations for Extrapolation of Efficacy from Adults to Children.

Journal Club Leona Isabella von Köckritz.

Robert A. Terkeltaub, Daniel E. Furst, Katherine Bennett, Karin A. Kook, R. S. Crockett, and Matthew W. Davis ARTHRITIS & RHEUMATISM Vol. 62, No. 4, April.

1 Once-daily indacaterol versus twice-daily salmeterol for COPD ; a placebo-controlled comparison R2 정명화 Eur Respir J 2011; 37: 273–279.

Antibiotics in Addition to Systemic Corticosteroids for Acute Exacerbations of Chronic Obstructive Pulmonary Disease Johannes M.A. Daniels; Dominic snijders;

CHEST 2013; 144(3): R3 김유진 / Prof. 장나은. Introduction 2  Cardiovascular diseases  common, serious comorbid conditions in patients with COPD cardiac.

MIGUEL REGUEIRO, WOLFGANG SCHRAUT, LEONARD BAIDOO, KEVIN E. KIP, ANTONIA R. SEPULVEDA, MARILYN PESCI, JANET HARRISON, SCOTT E. PLEVY GASTROENTEROLOGY 2009;136:441–450.

GASTROENTEROLOGY 2008; 134 :688–695 소화기내과 R4 이 재 연.

내과 R2 이지영. INTRODUCTION  Asthma  Allergic airway inflammation,Th2-weighted process  Biomarkers  Phenotypic distinctions  Development of personalized.

Evaluation of combined middle and inferior meatal antrostomies for endonasal eradication of severe maxillary sinusitis Adel Said El-Antably.

Immunotherapy for Allergic Rhinitis

Eucrisa™ - Crisaborole

Kavita, Dinesh Kumar Sharma, Renu Vij, Jatinder Singh

Mustafa Serinken MD, Cenker Eken MD, Kamil Tunay MD, Yalcin

Farletuzumab in platinum sensitive ovarian cancer with low CA125

Addition of Inhaled Tobramycin to Ciprofloxacin for Acute Exacerbations of Pseudomonas aeruginosa Infection in Adult Bronchiectasis* Diana Bilton, MD;

Treatment of nasal polyposis and chronic rhinosinusitis with fluticasone propionate nasal drops reduces need for sinus surgery Albertien A.C. Aukema,

S1207: Phase III randomized, placebo-controlled trial adding 1 year of everolimus to adjuvant endocrine therapy for patients with high-risk, HR+, HER2-

Diagnosis, Evaluation, and Therapy for Severe Refractory Eosinophilic Asthma.

Alalia Berry, MD, William W. Busse, MD

Claus Bachert, PhD, Ana R. Sousa, PhD, Valerie J. Lund, MD, Glenis K

Treatment of chronic rhinosinusitis with intranasal amphotericin B: A randomized, placebo-controlled, double-blind pilot trial Jens U. Ponikau, MD, David.

Oral steroids and doxycycline: Two different approaches to treat nasal polyps Thibaut Van Zele, MD, PhD, Philippe Gevaert, MD, PhD, Gabriele Holtappels,

A review of treatment with mepolizumab, an anti–IL-5 mAb, in hypereosinophilic syndromes and asthma William W. Busse, MD, Johannes Ring, MD, PhD, Johannes.

Mepolizumab, a humanized anti–IL-5 mAb, as a treatment option for severe nasal polyposis Philippe Gevaert, MD, PhD, Nicholas Van Bruaene, MD, Tom Cattaert,

Comparison of the efficacy of budesonide and fluticasone propionate aqueous nasal spray for once daily treatment of perennial allergic rhinitis James.

Allergic rhinobronchitis: The asthma–allergic rhinitis link

Effect of budesonide transnasal nebulization in patients with eosinophilic chronic rhinosinusitis with nasal polyps Chengshuo Wang, MD, Hongfei Lou,

The efficacy and safety of omalizumab in pediatric allergic asthma

Subjective and objective assessments in patients with seasonal allergic rhinitis: Effects of therapy with mometasone furoate nasal spray Eli O. Meltzer,

Peter S. Creticos, MD Journal of Allergy and Clinical Immunology

Different types of T-effector cells orchestrate mucosal inflammation in chronic sinus disease Nan Zhang, MD, PhD, Thibaut Van Zele, MD, PhD, Claudina.

Clinical effects of nedocromil sodium on challenges invoking neuronal mechanisms and on virally induced symptoms Peter König, MD, PhD Journal of Allergy.

Allergic rhinitis Journal of Allergy and Clinical Immunology

Claus Bachert, MD, PhD, Luo Zhang, MD, Phillippe Gevaert, MD

Staphylococcus aureus enterotoxin B, protein A, and lipoteichoic acid stimulations in nasal polyps Joke Patou, MD, Philippe Gevaert, MD, PhD, Thibaut.

Short course of systemic corticosteroids in sinonasal polyposis: A double-blind, randomized, placebo-controlled trial with evaluation of outcome measures

The correlation between allergic rhinitis and sleep disturbance

Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma Philippe Gevaert, MD, PhD, Lien Calus, MD, Thibaut Van Zele,

A randomized controlled study evaluating medical treatment versus surgical treatment in addition to medical treatment of nasal polyposis Ebba Hedén Blomqvist,

Presentation transcript:

Upper Airways Research Laboratory Department of Otorhinolaryngology Advanced treatments of nasal polyposis: Anti-IL-5 and Anti-IgE Which for whom? Prof. Dr. Philippe Gevaert Department of Otorhinolaryngology Ghent University Hospital, Belgium

Upper Airways Research Laboratory Department of Otorhinolaryngology Advanced medical treatments in recurrent nasal polyposis Surgery = removing immunological memory

Upper Airways Research Laboratory Department of Otorhinolaryngology Antibiotics Anti IL-5 Anti-IL-5 Corticosteroids IL-5 ECP Eotaxin IgE Anti IL-5 Advanced medical treatments in recurrent nasal polyposis

Upper Airways Research Laboratory Department of Otorhinolaryngology N=354 J Allergy Clin Immunol 2005;116:

Upper Airways Research Laboratory Department of Otorhinolaryngology Nasal corticosteroid DROPS in nasal polyps double-blind, placebo-controlled study with nasal GCS drops After 12-weeks:  nasal blockage,  peak nasal inspiratory flow  polyp volume (CT score)  need for sinus surgery Aukema, Mulder, Fokkens; JACI 2005

Upper Airways Research Laboratory Department of Otorhinolaryngology Participating centers: ENT Dept: University Hospital Ghent, Belgium, University Hospital St. Rafael Leuven Belgium; University Hospital Erlangen, Germany, Adelaide University Hospital, Australia, Academic Medical Center, Amsterdam, the Netherlands T Van Zele, Gevaert P (in preparation) Oral steroids in nasal polyps: a 3-month double blind, randomized, placebo-controlled trial DBPC in 32 patient with nasal polyps, 20days methylprednisolon (Day mg, day mg, day mg) Primary endpoint: endoscopic scoring with a five grade system Secoundary endpoints symptoms evaluation of local and systemical biological activity and efficacy measurement of IgE, IL-5 and ECP on nasal secretions (merocell) measurement of blood eosinophilia daily measurement of nasal peak inspiratory flow grade

Upper Airways Research Laboratory Department of Otorhinolaryngology Thibaut Van Zele, Philippe Gevaert, Gabriele Holtappels, Achim Beule, Peter John Wormald, Susanne Mayr, Greet Hens, Peter Hellings, Fenna A Ebbens, Paul Van Cauwenberge, Claus Bachert Oral steroids in nasal polyps: a 3-month double blind, randomized, placebo-controlled trial DBPC in 32 patient with nasal polyps, 20days methylprednisolon (Day mg, day mg, day mg)

Upper Airways Research Laboratory Department of Otorhinolaryngology Methylprednisolone has mild local anti-inflammatory effects Placebogroup: n=18 Methylprednisolone group: n=14 T Van Zele, Gevaert P (in preparation)

Upper Airways Research Laboratory Department of Otorhinolaryngology Antibiotics Anti IL-5 Anti-IL-5 Corticosteroids IL-5 ECP Eotaxin IgE Advanced medical treatments in recurrent nasal polyposis

Upper Airways Research Laboratory Department of Otorhinolaryngology Long term antibiotic treatment in NP DBPC study in 90 patients: 3m low-dose erythromycin, nasal douche, nasal GCS vs. sinus surgery 50% Improvement of symptoms no difference vs sinus surgery

Upper Airways Research Laboratory Department of Otorhinolaryngology

Upper Airways Research Laboratory Department of Otorhinolaryngology * Doxycycline reduces MMP9, ECP, MPO and nasal polyp size, in a double-blind, randomized, placebo controlled, multicenter trial. 20 days doxycycline (100mg/d) reduces PND Philippe Gevaert, Thibaut Van Zele, Gabriele Holtappels, Achim Beule, Peter John Wormald, Susanne Mayr, Greet Hens, Peter Hellings, Fenna A Ebbens, Paul Van Cauwenberge, Claus Bachert

Upper Airways Research Laboratory Department of Otorhinolaryngology Placebo group: n=18 Methylprednisolone group: n=14 Oral doxycycline reduces neutrophilic and eosinophilic inflammation Gevaert P, Van Zele T (in preparation)

Upper Airways Research Laboratory Department of Otorhinolaryngology First double blind placebo controlled trial with antibiotics in nasal polyps that shows: a significant effect of doxycycline on nasal polyp size Doxycycline reduces local inflammation in terms of ECP and MPO effect on eosinophilic inflammation effect on neutrophilic (may be related to the effect on S. aureus) Doxycycline has a sigificant effect on remodeling (MMP-9) Doxycycline Gevaert P, Van Zele T (in preparation)

Upper Airways Research Laboratory Department of Otorhinolaryngology Practical management of Nasal Polyposis Nasal douche with saline Nasal corticosteroids GCS sprays: 2x/d, symptoms↓, no resolution of NP GCS drops: symptoms↓, surgery↓↓ Oral corticoids: effective but fast recurrence Antibiotics: Antibiotic ointment Long-term antibiotics: macrolides 500mg/d ged 3m doxycycline 100 mg/d ged 1m Combinations? Endoscopic sinus surgery: only chance for cure!! in NP: recurrences

Upper Airways Research Laboratory Department of Otorhinolaryngology Treatment of nasal polyposis following EP³OS

Upper Airways Research Laboratory Department of Otorhinolaryngology Antibiotics Anti IL-5 Anti-IL-5 Corticosteroids Advanced medical treatments in recurrent nasal polyposis

Upper Airways Research Laboratory Department of Otorhinolaryngology IL-5 and eosinophils in nasal polyposis  ECP   IL-5  IL-5        Migration Homing Survival Activation Maturation Differentiation Recruitement IL5 + Eotaxin

Upper Airways Research Laboratory Department of Otorhinolaryngology  ECP   IL-5  IL-5        Migration Homing Survival Activation Maturation Differentiation Recruitement IL5 + Eotaxin Anti-interleukin 5 in nasal polyposis Anti IL-5 x x x

Upper Airways Research Laboratory Department of Otorhinolaryngology Objective and study design To asses the therapeutic potential of two injections of 750 mg IV mepolizumab (28days) endoscopic score symptom scores CT scan Two-arm, randomized, double blind, placebo controlled, trial 30 Subjects Severe nasal polyps 20 Subjects 10 Subjects Weeks * MEPO 750mg IV Placebo Dosing Follow up * Primary endpoint

Upper Airways Research Laboratory Department of Otorhinolaryngology Endpoints Primary endpoint Endoscopic Nasal polyp score 8 weeks post 1 st dosing Secondary endpoints CT scan assessment (blinded) Difference 50% Symptom score Peak nasal inspiratory flow nasal (merocel) and systemic Inflammatory mediators Score

Upper Airways Research Laboratory Department of Otorhinolaryngology Endoscopic Nasal polyp score and improvement * *  intranasal steroids permitted 10/20 12/20 13/20

Upper Airways Research Laboratory Department of Otorhinolaryngology Need for surgery - Number of exclusions (= sytemic steroids or AB or surgery) p=0.03 **

Upper Airways Research Laboratory Department of Otorhinolaryngology CT scores improvement from baseline at week 8

Upper Airways Research Laboratory Department of Otorhinolaryngology 8 weeks post 1 st Mepo dose Baseline CT SCAN

Upper Airways Research Laboratory Department of Otorhinolaryngology Symptoms  intranasal steroids permitted

Upper Airways Research Laboratory Department of Otorhinolaryngology Peak nasal inspiratory flow (change from baseline)

Upper Airways Research Laboratory Department of Otorhinolaryngology Anti IgE in nasal polyposis 24 patients:16 got anti-IgE 8 got placebo 4 (evt 8) Injections over 3 months  IgE ? Local Anti-IgE Concentration? Anti IgE x  IgE x

Improvement in total nasal polyp score Omalizumab (n=15) versus placebo (n=8)

Improvement in symptoms Omalizumab (n=15) versus placebo (n=8)

UPSIT smell test

Upper Airways Research Laboratory Department of Otorhinolaryngology CT-scans before and after Anti-IgE

Upper Airways Research Laboratory Department of Otorhinolaryngology CT-scans before and after Anti-IgE

Upper Airways Research Laboratory Department of Otorhinolaryngology CT-scans before and after Anti-IgE better obsAbetter obsB mean percentage improvement placebo omalizumab

Upper Airways Research Laboratory Department of Otorhinolaryngology Allergic versus non allergic patients

Upper Airways Research Laboratory Department of Otorhinolaryngology Anti IgE Anti-IgE Antibiotics Vaccination IL-5 ECP Eotaxin IgE Anti IL-5 Anti-IL-5 Corticosteroids First DBPC finished in 24 NP patients In Ghent New multicenter trial started with 120 NP patients Future therapeutic options in nasal polyposis

Upper Airways Research Laboratory Department of Otorhinolaryngology Practical management of Nasal Polyposis Nasal douche with saline Nasal corticosteroids GCS sprays: 2x/d, symptoms↓, no resolution of NP GCS drops: symptoms↓, surgery↓↓ Oral corticoids: effective but fast recurrence Antibiotics: Antibiotic ointment Long-term antibiotics: macrolides 500mg/d ged 3m doxycycline 100 mg/d ged 1m Future: Omalizumab (antiIgE) allergic 85% vs non allergic NP 55% Mepolizumab (anti-IL5): 2 injections in 65% better

Upper Airways Research Laboratory Department of Otorhinolaryngology Upper Airways Research Laboratory 2009